Company / Cash & Equivalents
LIGAND PHARMACEUTICALS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$174.9M
FY2025
5-year range
$19.5M / $174.9M
FY2021-FY2025
Trend
+141.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $19M in FY2016 to $175M in FY2025.
Based on SEC 10-K filings.
$175M in FY2025 with a 5-year CAGR of +29.7%.
Improved from $23M to $175M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +57.2%
- 5-Year CAGR
- +29.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +29.7%, indicating consistent growth.
- In FY2025, cash & equivalents increased 141.9% year-over-year.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $174.9M | +141.9% |
| FY2024 | $72.3M | +215.0% |
| FY2023 | $23.0M | -49.0% |
| FY2022 | $45.0M | +130.5% |
| FY2021 | $19.5M | -59.0% |
| FY2020 | $47.6M | -33.4% |
| FY2019 | $71.5M | -38.9% |
| FY2018 | $117.2M | +468.2% |
| FY2017 | $20.6M | +10.0% |
| FY2016 | $18.8M | -80.8% |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026